Therefore, our study finding of the decreased percentage of CD40+ and CD192+CD14+CD16++ monocytes probably indicates the beneficial effects of ocrelizumab therapy, which causes decreased entrance of monocytes into the CNS and decreased T and B cell activation compared to untreated PPMS subjects. This evidence concerns the gene CCR2 and primary progressive multiple sclerosis.